lncRNA FOXP4-AS1 在癌症患者中的临床预后价值：基于 TCGA 数据集的荟萃分析和生物信息学分析。

The clinical prognostic value of lncRNA FOXP4-AS1 in cancer patients: A meta-analysis and bioinformatics analysis based on TCGA datasets.

机构信息

Department of Hepatic-Biliary-Pancreatic Surgery, The Neijiang First People's Hospital affiliated to Chongqing Medical University, Neijiang City, Sichuan Province, China.

Department of Hospital Infection Management, The Neijiang Hospital of Traditional Chinese Medicine, Neijiang City, Sichuan Province, China.

出版信息

Medicine (Baltimore). 2022 Oct 21;101(42):e31439. doi: 10.1097/MD.0000000000031439.

DOI:10.1097/MD.0000000000031439

PMID:36281152

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9592412/

Abstract

BACKGROUND

The mortality and recurrence of patients with cancer is of high prevalence. Long non-coding RNA (lncRNA) forkhead box P4 antisense RNA 1 (FOXP4-AS1) is a promising lncRNA. There is increasing evidence that lncRNA FOXP4-AS1 is abnormally expressed in various tumors and is associated with cancer prognosis. This study was designed to identify the prognostic value of lncRNA FOXP4-AS1 in human malignancies.

METHODS

We searched electronic databases up to April 29, 2022, including PubMed, Cochrane Library, Embase, MEDLINE, and Web of Science. Eligible studies that evaluated the clinicopathological and prognostic role of lncRNA FOXP4-AS1 in patients with malignant tumors were included. The pooled odds ratios (ORs) and the hazard ratios (HRs) were calculated to assess the role of lncRNA FOXP4-AS1 using Stata/SE 16.1 software.

RESULTS

A total of 6 studies on cancer patients were included in the present meta-analysis. The combined results revealed that high expression of lncRNA FOXP4-AS1 was significantly associated with unfavorable overall survival (OS) (HR = 1.99, 95% confidence interval [CI]: 1.65-2.39, P < .00001), and poor disease-free survival (DFS) (HR = 1.81, 95% CI: 1.54-2.13, P < .00001) in a variety of cancers. In additional, the increase in lncRNA FOXP4-AS1 expression was also correlated with tumor size ((larger vs smaller) (OR = 3.16, 95% CI: 2.12-4.71, P < .00001), alpha-fetoprotein (≥400 vs <400) (OR = 3.81, 95%CI: 2.38-6.11, P = .83), lymph node metastasis (positive vs negative) (OR = 2.93, 95%CI: 1.51-5.68, P = .001), and age (younger vs older) (OR = 2.06, 95% CI: 1.41-3.00, P = .00002) in patients with cancer. Furthermore, analysis results using The Cancer Genome Atlas (TCGA) dataset showed that the expression level of lncRNA FOXP4-AS1 was higher in most tumor tissues than in the corresponding normal tissues, which predicted a worse prognosis.

CONCLUSIONS

In this meta-analysis, we demonstrate that high lncRNA FOXP4-AS1 expression may become a potential marker to predict cancer prognosis.

摘要

背景

癌症患者的死亡率和复发率普遍较高。长链非编码 RNA（lncRNA）叉头框 P4 反义 RNA 1（FOXP4-AS1）是一种很有前途的 lncRNA。越来越多的证据表明，lncRNA FOXP4-AS1 在各种肿瘤中异常表达，并与癌症预后相关。本研究旨在确定 lncRNA FOXP4-AS1 在人类恶性肿瘤中的预后价值。

方法

我们检索了截至 2022 年 4 月 29 日的电子数据库，包括 PubMed、Cochrane 图书馆、Embase、MEDLINE 和 Web of Science。纳入评估 lncRNA FOXP4-AS1 在恶性肿瘤患者的临床病理和预后作用的合格研究。使用 Stata/SE 16.1 软件计算合并的优势比（OR）和风险比（HR），以评估 lncRNA FOXP4-AS1 的作用。

结果

本荟萃分析共纳入 6 项癌症患者的研究。合并结果显示，lncRNA FOXP4-AS1 高表达与不良总生存期（OS）（HR=1.99，95%置信区间[CI]：1.65-2.39，P<.00001）和不良无病生存期（DFS）（HR=1.81，95%CI：1.54-2.13，P<.00001）显著相关。此外，lncRNA FOXP4-AS1 表达的增加与肿瘤大小（（较大 vs 较小）（OR=3.16，95%CI：2.12-4.71，P<.00001）、甲胎蛋白（≥400 vs <400）（OR=3.81，95%CI：2.38-6.11，P=.83）、淋巴结转移（阳性 vs 阴性）（OR=2.93，95%CI：1.51-5.68，P=.001）和年龄（年轻 vs 年老）（OR=2.06，95%CI：1.41-3.00，P=0.00002）有关。此外，使用癌症基因组图谱（TCGA）数据集的分析结果表明，lncRNA FOXP4-AS1 的表达水平在大多数肿瘤组织中高于相应的正常组织，这预示着预后较差。